5/23
06:54 am
etnb
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy May 23, 2024 6:32 AM ET 1 Like [Seeking Alpha]
Medium
Report
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy May 23, 2024 6:32 AM ET 1 Like [Seeking Alpha]
5/22
04:17 pm
etnb
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress [Yahoo! Finance]
Medium
Report
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress [Yahoo! Finance]
5/22
04:05 pm
etnb
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
Medium
Report
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
5/17
10:03 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
Medium
Report
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
5/16
08:15 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
5/15
09:30 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Evercore ISI from $37.00 to $33.00. They now have an "outperform" rating on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Evercore ISI from $37.00 to $33.00. They now have an "outperform" rating on the stock.
5/14
08:15 am
etnb
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]
Medium
Report
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]
5/14
08:00 am
etnb
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
Medium
Report
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
5/10
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/10
08:38 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at HC Wainwright from $31.00 to $29.00. They now have a "buy" rating on the stock.
Medium
Report
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at HC Wainwright from $31.00 to $29.00. They now have a "buy" rating on the stock.
5/9
04:24 pm
etnb
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/9
04:05 pm
etnb
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/8
04:05 pm
etnb
89bio to Participate in the BofA Securities 2024 Health Care Conference
Low
Report
89bio to Participate in the BofA Securities 2024 Health Care Conference
5/2
04:13 pm
etnb
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH [Yahoo! Finance]
Medium
Report
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH [Yahoo! Finance]
5/2
04:05 pm
etnb
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
Medium
Report
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
4/22
08:09 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
Neutral
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
4/17
04:19 pm
etnb
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]
Medium
Report
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]
4/17
04:05 pm
etnb
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Medium
Report
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
4/5
04:17 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/5
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/5
10:25 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
3/27
02:11 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
3/27
08:21 am
etnb
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis [Yahoo! Finance]
Low
Report
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis [Yahoo! Finance]
3/27
08:00 am
etnb
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Low
Report
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
3/18
03:14 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.